SCHEMBL4648546

SCHEMBL4648546

O=C1CN(c2cc(-c3ccoc3)ccc2OCc2ccccc2)S(=O)(=O)N1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 6/20 0.57
HSP90AB1 P08238 1/20 0.36
SNRNP200 O75643 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PTP4A3 O75365 1/20 0.35
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
HTR1A P08908 1/20 0.34
SLC6A2 P23975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4308578 0.92 PTPN1 (0.49) PTPN1HSP90AB1SNRNP200MEN1KMT2A
SCHEMBL4643501 0.84 PTPN1 (0.62) PTPN1SNRNP200PTP4A3HTR1ASLC6A2
SCHEMBL4646366 0.83 PTPN1 (0.61) PTPN1SNRNP200PTP4A3HTR1ASLC6A2
SCHEMBL4646708 0.82 PTPN1 (0.60) PTPN1PTP4A3LMNABRD4
SCHEMBL3920457 0.80 PTPN1 (0.61) PTPN1SNRNP200PTP4A3HTR1ASLC6A2
SCHEMBL4643306 0.80 PTPN1 (0.53) PTPN1PTP4A3ALDH1A1CYP1A2SLC6A4
SCHEMBL4646906 0.80 PTPN1 (0.53) PTPN1SNRNP200MAPTHTR1ASLC6A2
SCHEMBL4646595 0.80 PTPN1 (0.53) PTPN1SNRNP200CYP2C9HTR1ASLC6A2
SCHEMBL4646706 0.79 PTPN1 (0.57) PTPN1SNRNP200PTP4A3BRD4
Potassium SCHEMBL4647048 0.78 PTPN1 (0.50) PTPN1SNRNP200MAPTALDH1A1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293782-A1 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors NOVARTIS AG (CH) 2008-11-27 US disclosed
EP-1960377-A1 l , l , 3-TRI0X0-l , 2 , 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS Novartis AG (CH) 2008-08-27 EP disclosed
WO-2007067614-A1 l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293782-A1 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors PTPRS, IRS1, PTPMT1 PTPN1 10/4885HSP90AB1 1760/4885SNRNP200 3957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.